The original version of this article unfortunately included a mistake in Fig. 2b where the images of mice in the tumour control group (right), day 30 (bottom) should be removed as the wrong images (duplicate of day 17) were inserted by mistake. At this time point the tumour control mice were no longer alive and the images were replaced by black areas.
The revised Fig. 2 is placed on the following page.
Fig. 2
In vivo efficacy of transiently transfected T cells depends on route of administration. (a) NSG mice were injected i.p. with 106 HCT 116 ff-Luc 2 days before injection of T cells. T cell treated groups were treated on days 2, 4, 8, 11, and 16 with Radium-1 TCR or irrelevant TCR expressing T cells i.p. (n = 10). The Radium-1 TCR group was treated with 107 Radium-1 TCR electroporated T cells at each injection, the irrelevant TCR group (n = 10) was treated with 107 DMF5 TCR electroporated T cells at each injection i.p. Tumour control received no treatment (n = 4). Three mice from each group are shown. (b) Tumour load was evaluated by bioluminescence imaging on days 2, 9, 17, 23, and 30. Black areas indicate loss of mice. (c) Average tumour load (total flux photons/s) in the different groups are shown (p = 0.031 and 0.0089). (d) Survival time of the different treatment groups after tumour injection (p = 0.0072). The results shown are representative of three independent experiments. (e) Radium-1 Tc treated group (n = 5) and mock electroporated Tc treated group (n = 4) were treated with 107 T cells i.v. at indicated time points. The tumour control group (n = 3) was not given any treatment. (f) Tumour load was evaluated by bioluminescence imaging on days 2, 7, 17, and 29. (g) Average tumour load (total flux photons/s) in animals given T cells i.v. and control group, (h) Kaplan–Meier animals given T cells i.v. and control group
×
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
